These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33581551)

  • 21. Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies.
    Saidahmatov A; Li J; Xu S; Hu X; Gao X; Kan W; Gao L; Li C; Shi Y; Sheng L; Wang P; Zhou Y; Liang X; Li J; Liu H
    J Med Chem; 2024 Sep; 67(17):15220-15245. PubMed ID: 39178382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
    Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
    Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
    Hole AJ; Baumli S; Shao H; Shi S; Huang S; Pepper C; Fischer PM; Wang S; Endicott JA; Noble ME
    J Med Chem; 2013 Feb; 56(3):660-70. PubMed ID: 23252711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
    Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
    Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
    Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
    Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and bioevaluation of N-trisubstituted pyrimidine derivatives as potent aurora A kinase inhibitors.
    Luo Y; Deng YQ; Wang J; Long ZJ; Tu ZC; Peng W; Zhang JQ; Liu Q; Lu G
    Eur J Med Chem; 2014 May; 78():65-71. PubMed ID: 24681066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines.
    Salem MSH; Abdel Aziz YM; Elgawish MS; Said MM; Abouzid KAM
    Bioorg Chem; 2020 Jan; 94():103472. PubMed ID: 31813475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.
    Zhang JQ; Luo YJ; Xiong YS; Yu Y; Tu ZC; Long ZJ; Lai XJ; Chen HX; Luo Y; Weng J; Lu G
    J Med Chem; 2016 Aug; 59(15):7268-74. PubMed ID: 27427973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
    King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
    Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
    Wang S; Zhang RH; Zhang H; Wang YC; Yang D; Zhao YL; Yan GY; Xu GB; Guan HY; Zhou YH; Cui DB; Liu T; Li YJ; Liao SG; Zhou M
    Eur J Med Chem; 2021 Oct; 222():113573. PubMed ID: 34091209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
    Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T
    J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
    Metwally NH; Mohamed MS; Ragb EA
    Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
    Wang WJ; Gao L; Wang S; Huang W; Meng XY; Hu H; Chen Z; Sun J; Yuan Y; Zhou Y; Diao X; Huang R; Li J; Chen XH
    J Med Chem; 2024 Jun; 67(12):10035-10056. PubMed ID: 38885173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
    AboulWafa OM; Daabees HMG; Badawi WA
    Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
    Jing L; Tang Y; Xiao Z
    Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting CDK9 for treatment of colorectal cancer.
    Rahaman MH; Lam F; Zhong L; Teo T; Adams J; Yu M; Milne RW; Pepper C; Lokman NA; Ricciardelli C; Oehler MK; Wang S
    Mol Oncol; 2019 Oct; 13(10):2178-2193. PubMed ID: 31398271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
    Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
    Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.